Who is sponsoring NCT03717610?

NCT03717610 is sponsored by Uppsala University Hospital.

What drugs are being tested in NCT03717610?

Interventions in NCT03717610: radical surgery with HIPEC.

What condition does NCT03717610 study?

NCT03717610 studies Ovarian Cancer Recurrent.

Is NCT03717610 still recruiting?

NCT03717610 is currently status unknown. Last updated 8 October 2021.

Last reviewed 2021-10-08 · How we verify

NCT03717610

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer

Status unknown NA Last updated 8 October 2021

What this trial tests

NA trial testing radical surgery with HIPEC in Ovarian Cancer Recurrent in 10 participants. Status unknown.

Timeline

4 October 2018

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Uppsala University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	10
Start date	4 October 2018
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Sweden

Drugs / interventions tested

radical surgery with HIPEC

Conditions studied

Ovarian Cancer Recurrent — all drugs for Ovarian Cancer Recurrent →

Sponsor

Uppsala University Hospital

Who can join

Adults 18 to 70, female only, with Ovarian Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a feasibility single-center study to investigate the tolerability, toxicity, quality of life, morbidity, mortality of the HIPEC treatment following cytoreductive surgery for treatment of recurrent ovarian, peritoneal, and fallopian tube cancers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Research and Development in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)-A Cross-Sectional Analysis of Clinical Trials Registered on ClinicalTrials.gov.
Ukegjini K, Guidi M, Lehmann K, Süveg K, et al · · 2023 · cited 7× · PMID 37046587 · DOI 10.3390/cancers15071926

Verify or expand the search:

Other recruiting trials for Ovarian Cancer Recurrent

Currently open trials in the same condition.

NCT07030907 — A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer · Phase 1 · recruiting
NCT06843447 — A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · Phase 1, PHASE2 · recruiting
NCT06791460 — Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer · Phase 2, PHASE3 · recruiting
NCT06660511 — Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Tr · EARLY_PHASE1 · recruiting
NCT05990192 — SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy · Phase 2 · recruiting

Other Uppsala University Hospital trials

Trials by the same sponsor.

NCT06848660 — Study on Orthosis in Cervical Spine Fracture Treatment · NA · recruiting
NCT06610214 — IMPACT-care (Improved Medication Communication and Patient Involvement at Care Transitions) · NA · completed
NCT06621381 — Concentrated Exposure and Response Prevention for Children With Obsessive-compulsive Disorder · NA · recruiting
NCT06372444 — Mechanisms of Acute Kidney Injury in Severe Infections · recruiting
NCT06261411 — Lung Ultrasound as Alternative to Radiography in Thoracic Surgery · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03717610 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Uppsala University Hospital
Last refreshed: 8 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing